Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2+ Metastatic Breast Cancer (MBC) 1

Interventions

pembrolizumab 42 Carboplatin 38 Cisplatin 34 Paclitaxel 27 Pemetrexed 23 Gemcitabine 23 Nivolumab 22 Dexamethasone 17 Ipilimumab 16 Rituximab 15 Fluorouracil 14 Capecitabine 14 Docetaxel 13 trastuzumab deruxtecan 12 durvalumab 12 atezolizumab 12 Cyclophosphamide 12 Trastuzumab 11 Lenalidomide 11 olaparib 10 130-nm albumin-bound paclitaxel 10 Prednisone 9 venetoclax 8 daratumumab 8 Oxaliplatin 8 Cytarabine 8 Bortezomib 8 Bevacizumab 8 zanubrutinib 7 Vinorelbine 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has announcements × Lapatinib × Clear all

NCT01808573 2021-06-11

NALA

Puma Biotechnology, Inc.

Phase 3 Completed

621 enrolled 21 charts 1 FDA

HER2+ Metastatic Breast Cancer (MBC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡